NASDAQ:RCKT

Rocket Pharmaceuticals (RCKT) Stock Forecast, Price & News

$21.84

+0.91 (+4.35%)

(As of 06/2/2023 08:48 PM ET)

Compare

Today's Range: $21.07
▼
$21.88
50-Day Range: $15.79
▼
$22.24
52-Week Range: $9.50
▼
$23.48

Volume: 602,600 shs
Average Volume: 790,099 shs
Market Capitalization: $1.76 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $51.09

Rocket Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 133.9% Upside
$51.09 Price Target
Short Interest: Bearish
10.07% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.81
Upright™ Environmental Score
News Sentiment: 0.16
Based on 14 Articles This Week
Insider Trading: Selling Shares
$43,678 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.08) to ($2.12) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars

Medical Sector

225th out of 980 stocks

Pharmaceutical Preparations Industry

103rd out of 485 stocks

3.5

Analyst's Opinion

Consensus Rating
Rocket Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 12 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $51.09, Rocket Pharmaceuticals has a forecasted upside of 133.9% from its current price of $21.84.
Amount of Analyst Coverage
Rocket Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
10.07% of the outstanding shares of Rocket Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Rocket Pharmaceuticals has a short interest ratio ("days to cover") of 9.8.
Change versus previous month
Short interest in Rocket Pharmaceuticals has recently increased by 0.87%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Rocket Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Rocket Pharmaceuticals does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Rocket Pharmaceuticals has received a 74.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Rocket Pharmaceuticals is -0.81.

1.8

News and Social Media Coverage

News Sentiment
Rocket Pharmaceuticals has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 14 news articles for Rocket Pharmaceuticals this week, compared to 8 articles on an average week.
Search Interest
Only 19 people have searched for RCKT on MarketBeat in the last 30 days. This is a decrease of -32% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Rocket Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -70% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Rocket Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $43,678.00 in company stock.
Percentage Held by Insiders
33.67% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
93.23% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Rocket Pharmaceuticals are expected to grow in the coming year, from ($3.08) to ($2.12) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Rocket Pharmaceuticals is -6.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Rocket Pharmaceuticals is -6.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Rocket Pharmaceuticals has a P/B Ratio of 3.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Rocket Pharmaceuticals (NASDAQ:RCKT) Stock

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

Receive RCKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RCKT Stock News Headlines

June 3, 2023 | bbc.com

Rocket League: Exeter-based IT firm Timewade wins esports event

June 2, 2023 | fxstreet.com

RPL price coils up for a breakout fueled by a 70% rise in Rocket Pool network growth

June 5, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

June 2, 2023 | fxstreet.com

Lido Finance, Rocket Pool tokens rally as traders stake $180 million in Ethereum within 48 hours

June 2, 2023 | msn.com

Rocket Lab delays its Venus atmospheric probe mission

June 1, 2023 | msn.com

Rocket Lab’s private mission to Venus slips to 2025

June 1, 2023 | detroitnews.com

EMBARGO: Rocket's housing stability initiative returns to in-person canvassing

June 1, 2023 | detroitnews.com

Young gun Tom Kim, fan favorite Max Homa returning to Rocket Mortgage Classic

June 5, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

June 1, 2023 | msn.com

Poarch Creek Indians donate $2.5 million to Space & Rocket Center

May 31, 2023 | forbes.com

G2 Esports Reveals All-Women ‘Rocket League’ Team For North America

May 31, 2023 | msn.com

Jimmy Butler a Rocket? Houston offered four first-round picks to Minnesota but was turned down

May 31, 2023 | markets.businessinsider.com

Rocket Pharma Says EMA Grants PRIME Designation For RP-A501 Gene Therapy For Danon Disease

May 31, 2023 | finance.yahoo.com

Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease

May 30, 2023 | americanbankingnews.com

Critical Contrast: Sernova (OTCMKTS:SEOVF) versus Rocket Pharmaceuticals (NASDAQ:RCKT)

May 27, 2023 | msn.com

Former Rocket Eric Gordon gets brutally honest on 2018 Warriors series ending James Harden era

May 26, 2023 | msn.com

Quavo Huncho Spoke About Takeoff and His Track ‘Rocket Power’ – Takeoff’s Killer Formally Charged & More | Videos

May 25, 2023 | msn.com

Tom Izzo returns to defend title at Rocket Mortgage Classic celebrity scramble

May 24, 2023 | msn.com

Watch Rocket Lab launch 2 tiny NASA hurricane-watching probes early Thursday

May 24, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT), Option Care Health (OPCH) and Alpha Tau Medical Ltd (DRTS)

May 24, 2023 | msn.com

Quavo Shares ‘Rocket Power’ Album Update: “This Is My Therapy”

May 23, 2023 | yahoo.com

James Gunn Explains the Reason for Rocket’s Choice at the End of Guardians of the Galaxy Vol. 3

May 23, 2023 | finance.yahoo.com

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency (PKD)

May 22, 2023 | americanbankingnews.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Now Covered by Analysts at StockNews.com

May 19, 2023 | msn.com

Rocket at Alabama welcome center wins small victory for survival

May 19, 2023 | msn.com

Can Rocket Lab Stock Take You to the Moon?

May 19, 2023 | markets.businessinsider.com

Bank of America Securities Keeps Their Buy Rating on Rocket Pharmaceuticals (RCKT)

See More Headlines

RCKT Price History

30 days | 90 days | 365 days | Advanced Chart

RCKT Company Calendar

Last Earnings: 5/04/2023
Today: 6/04/2023
Next Earnings (Estimated): 8/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RCKT
CUSIP: N/A
CIK: 1281895
Web: www.rocketpharma.com
Phone: (609) 659-8001
Fax: 646-224-9585
Employees: 151
Year Founded: 2018

Price Target and Rating

Average Stock Price Forecast: $51.09
High Stock Price Forecast: $75.00
Low Stock Price Forecast: $34.00
Forecasted Upside/Downside: +133.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.35)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-221,860,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -55.70%
Return on Assets: -49.53%

Debt

Debt-to-Equity Ratio: 0.04
Current Ratio: 10.83
Quick Ratio: 10.83

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.70 per share
Price / Book: 3.83

Miscellaneous

Outstanding Shares: 80,460,000
Free Float: 53,370,000
Market Cap: $1.76 billion
Optionable: Optionable
Beta: 1.22

Social Links

Key Executives

Gaurav D. Shah
Chief Executive Officer & Director

Kinnari Patel
President & Chief Operating Officer

John C. Militello
Treasurer, Chief Financial & Accounting Officer

Mayo Pujols
Chief Technical Officer & Executive Vice President

Mark White
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RCKT Stock - Frequently Asked Questions

Should I buy or sell Rocket Pharmaceuticals stock right now?: 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last twelve months. There are currently 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RCKT shares.
View RCKT analyst ratings or view top-rated stocks.
What is Rocket Pharmaceuticals' stock price forecast for 2023?: 12 equities research analysts have issued 12-month price objectives for Rocket Pharmaceuticals' stock. Their RCKT share price forecasts range from $34.00 to $75.00. On average, they anticipate the company's stock price to reach $51.09 in the next year. This suggests a possible upside of 133.9% from the stock's current price.
View analysts price targets for RCKT or view top-rated stocks among Wall Street analysts.
How have RCKT shares performed in 2023?: Rocket Pharmaceuticals' stock was trading at $19.57 on January 1st, 2023. Since then, RCKT shares have increased by 11.6% and is now trading at $21.84.
View the best growth stocks for 2023 here.
When is Rocket Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our RCKT earnings forecast.
How were Rocket Pharmaceuticals' earnings last quarter?: Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) released its quarterly earnings data on Thursday, May, 4th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.11. During the same period in the prior year, the firm posted ($0.67) earnings per share.
What ETFs hold Rocket Pharmaceuticals' stock?: ETFs with the largest weight of Rocket Pharmaceuticals (NASDAQ:RCKT) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Global X Guru Index ETF (GURU), Harbor Health Care ETF (MEDI), ALPS Medical Breakthroughs ETF (SBIO), Harbor Disruptive Innovation ETF (INNO), Putnam BioRevolution ETF (SYNB), SPDR S&P Biotech ETF (XBI) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of Rocket Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA).
What is Rocket Pharmaceuticals' stock symbol?: Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."
Who are Rocket Pharmaceuticals' major shareholders?: Rocket Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.79%), Maverick Capital Ltd. (5.48%), Wellington Management Group LLP (5.11%), State Street Corp (5.00%), Westfield Capital Management Co. LP (4.02%) and Price T Rowe Associates Inc. MD (2.32%). Insiders that own company stock include Gaurav Shah, Gotham Makker, John Militello, Jonathan David Schwartz, Kinnari Patel and Rtw Investments, Lp.
View institutional ownership trends.
How do I buy shares of Rocket Pharmaceuticals?: Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Rocket Pharmaceuticals' stock price today?: One share of RCKT stock can currently be purchased for approximately $21.84.
How much money does Rocket Pharmaceuticals make?: Rocket Pharmaceuticals (NASDAQ:RCKT) has a market capitalization of $1.76 billion. The biotechnology company earns $-221,860,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis.
How many employees does Rocket Pharmaceuticals have?: The company employs 151 workers across the globe.
How can I contact Rocket Pharmaceuticals?: Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The official website for the company is www.rocketpharma.com. The biotechnology company can be reached via phone at (609) 659-8001, via email at investors@rocketpharma.com, or via fax at 646-224-9585.

This page (NASDAQ:RCKT) was last updated on 6/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial